Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

New heartburn medication meets expectations in drug trial
Posted: November 26, 2009

Swiss biotech group Addex Pharmaceuticals announced that its lead drug candidate met expectations in a mid-stage clinical trial in heartburn, setting the company up for a lucrative partnership with a bigger drug maker that would provide much-needed funds for the

FDA approves generic GERD treatment
Posted: November 25, 2009

The Food and Drug Administration (FDA) has approved a generic version of a drug for treating gastroesophageal reflux disease, or GERD, in adolescents and adults. Amneal Pharmaceuticals’ nizatidine oral solution was approved in the 15-mg-per-15-ml strength, and is a generic

Two breast cancer survivors awarded $100 million in HRT lawsuits
Posted: November 24, 2009

The message was heard loud and clear – powerful drug companies that make billions from products they know pose a significant risk of life-threatening health consequences to the people who take them, owe their victims. Big time. This week, Pfizer,

Despite risks and expense, FDA approves Gardasil for boys
Posted: November 24, 2009

The Advisory Committee on Immunization Practices, which informs the U.S. Food and Drug Administration on vaccine use and policy, declined to advocate for Gardasil’s systematic and widespread use in boys and men. The human papilloma virus, or HPV, does not

New study may lead to different treatments for GERD
Posted: November 24, 2009

Findings from a new study on the causes of gastroesophageal reflux disease (GERD) may lead to new way of treating the condition. According to a team of researchers from the University of Texas Southwestern Medical Center, GERD, which causes painful

More lawsuits filed against pain pump manufacturers
Posted: November 23, 2009

Five lawsuits against manufacturers of pain pumps and pharmaceutical companies on behalf of 28 people were filed in Los Angeles County Superior Court this month, alleging fraud, breach of warranty and products liability, saying the makers of the products continued

Reglan may stop hiccups, but may cause more serious problems
Posted: November 23, 2009

Most people who take the medication Reglan (metoclopramide) are prescribed the drug to treat heartburn, GERD, or gastroparesis, also known as slow emptying of the stomach. But metoclopramide may also halt persistent hiccups.

Bayer tests Google’s new ad format for Yaz promotion
Posted: November 18, 2009

A new ad format developed by Google for prescription drugs attaches a fixed link to sponsored results. When clicked, the link takes the browser to a page announcing  the drug’s side effects, risks, and other important information, much the same way as

Prepping bowel for colonoscopy is ‘necessary evil’
Posted: November 18, 2009

Let’s face it. There is no comfortable way to prepare for a colonoscopy. You can call it a necessary evil, but colon screenings are necessary for early detection of colorectal cancer for people ages 50 and older, those with a

New study shows vytorin and zetia less effective than niacin
Posted: November 17, 2009

Vytorin has struck out again, this time in a clinical trial that compared the drug’s safety and efficacy to a prescription form of the B vitamin niacin. The results of the trial, which the New England Journal of Medicine featured